Hungarian accident-involved drivers showed more benzodiazepines and SCRAs than…

Drug consumption pattern of drivers causing traffic accidents with a motor vehicle in Hungary (2014-2023).

Forensic science international • • Highly Relevant
🤖

AI Summary

This observational study characterized drug test results in 1,563 drivers classified by Hungarian police as at fault in a motor vehicle accident and tested on suspicion of drug use from 2014 to 2023. The researchers compared these results with a previously reported group of drivers suspected of drug-impaired driving at roadside checks in the same region and period. Overall, 83.7% of the accident-involved drivers tested positive; findings included classical illicit drugs, psychoactive medicines, synthetic cannabinoid receptor agonists (SCRAs) and stimulant new psychoactive substances.

Among medicine-positive cases, benzodiazepines accounted for 84.1%, and 55.6% of those cases exceeded the upper therapeutic limit. Compared with roadside-check drivers, accident-involved drivers more often tested positive for benzodiazepines and SCRAs, while active THC was more frequent in the roadside-check group. These are differences between two police-selected groups, not evidence that a substance caused an accident or that it carries a particular accident risk. The authors note that benzodiazepine-related impairment may be less conspicuous at roadside checks and could be under-detected. This abstract-based summary cannot establish causation or represent all drivers.

💡 Key Findings

1
83.7% of the 1,563 accident-involved drivers tested positive for at least one screened substance.
High
90%
2
Among medicine-positive cases, benzodiazepines made up 84.1%; 55.6% of these cases exceeded the upper therapeutic limit.
High
90%
3
Benzodiazepines and SCRAs were more frequent in the accident-involved group than in the roadside-check group, while active THC was more frequent in the roadside-check group.
High
90%
4
Because both groups were selected by police suspicion, the comparison shows relative enrichment, not accident risk or causation; the authors suggest benzodiazepine-related impairment may be under-detected at roadside checks.
High
95%

📄 Original Abstract

Driving under the influence of drugs (DUID) is a recognized risk factor for traffic accidents, but data on accident-involved drivers in Hungary are scarce. We characterized drug use among 1563 drivers classified by the police as at fault for a traffic accident and tested on suspicion of drug use (DCA) between 2014 and 2023, and compared their toxicological profile with a previously reported cohort of drivers suspected of DUID at roadside checks (sDUID) from the same region and period. Blood and urine samples were screened for illicit drugs, psychoactive medicines and new psychoactive substances by gas and liquid chromatography-mass spectrometry. Temporal trends were assessed using annual proportions of tested drivers and negative binomial regression with the annual number of tested drivers as an offset. Differences in the distribution of substance categories between DCA and sDUID drivers were assessed using Pearson's chi-square test, followed by post-hoc binomial tests with Bonferroni correction. Overall, 1308 drivers (83.7%) tested positive: classical illicit drugs in 48.6%, psychoactive medicines in 44.2%, synthetic cannabinoid receptor agonists (SCRA) in 15.4% and stimulant new psychoactive substances (sNPS) in 9.94%. Benzodiazepines accounted for 84.1% of medicine-positive cases and exceeded the upper therapeutic limit in 55.6% of these. Benzodiazepines and SCRA were more frequent among DCA than sDUID drivers, whereas active tetrahydrocannabinol was more frequent among sDUID drivers. National seizure trends broadly mirrored these prevalence. Because both cohorts were selected by police suspicion, these differences express relative enrichment rather than accident risk. They nevertheless indicate that benzodiazepine-related impairment is less conspicuous at roadside checks and may be systematically under-detected.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.